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Nonsteroidal anti-inﬂammatory drug (NSAID) hypersensitivity
is a common drug allergy, inwhich 2major phenotypes, respiratory
(aspirin-exacerbated respiratory disease [AERD]) and cutaneous
(aspirin-exacerbated cutaneous disease [AECD] or aspirin-
intolerant acute urticaria [AIAU]) types, are noted.1 Typical symp-
toms of the respiratory type of NSAID hypersensitivity are dyspnea,
cough, and rhinorrhea, while those of the cutaneous type are urti-
caria and angioedema. However, it is sometimes confused to estab-
lish in patients with chest tightness or dyspnea after ingestion of
NSAIDs because the symptoms may originated from bronchocon-
striction of AERD or from angioedema of AIAU.2 Periostin is an
extracellular matrix protein and structurally homologous with fas-
ciclin I, an insect adhesion molecule. The serum periostin level cor-
relates well with eosinophilic airway inﬂammation and considered
a prognostic factor for the treatment of lebrikizumab (amonoclonal
antibody to IL-13).3 Recent studies have shown that periostin con-
tributes to tissue remodeling and is increased in the serum or the
lesional tissue of allergic rhinitis/chronic rhinosinusitis, atopic
dermatitis, and asthma.4e7 In addition, the serum periostin level
is signiﬁcantly higher in AERD patients than in aspirin-tolerant
asthmatic patients because AERD shares Th2-mediated pathogen-
esis with eosinophilic asthma.8
We hypothesized that the serum periostin level would differ be-
tween respiratory and cutaneous types of NSAID hypersensitivity
because remodeling occurs in the respiratory type of hypersensitiv-
ity, but not in the cutaneous type. In the present study, we
compared serum periostin levels between respiratory and cuta-
neous types of NSAID hypersensitivity to evaluate the serum peri-
ostin level as a biomarker for differentiating between phenotypes
of NSAID hypersensitivity.
A total of 326 adult patients with NSAID hypersensitivity and 87
healthy normal control (NC) subjects were included in the study.
Serum samples were obtained with written informed consent.
The samples were frozen at 70 C after collection and thawed
immediately before use. Clinical data were obtained from the reg-
istry database and electronic medical records reviewed by the al-
lergy specialists. The protocols used in this study were approved
by the Institute Review Board of Ajou University Hospital. Accord-
ing to clinical data, NSAID hypersensitivity was classiﬁed into
AERD, AECD, and AIAU by the clinicians at the Department of Al-
lergy and Clinical Immunology. AERD was deﬁned by the presence
of recurrent typical clinical history (development of respiratoryPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).tract symptoms after ingestion of aspirin or other NSAIDs) and/or
positive results to the lysine-aspirin bronchoprovocation test.
AECD referred to a chronic urticaria exacerbated after aspirin/
NSAID exposure, while acute urticaria was provoked only after
ingestion of the drug in AIAU.9 Serum periostin levels were
measured by using a proprietary sandwich ELISA (Shino-Test, Kana-
gawa, Japan) on duplicated samples as previously described (see
Measurement of serum periostin).10 Periostin levels were
compared among individual groups using Student's t-test and anal-
ysis of variance (ANOVA). Receiver operating characteristic (ROC)
curve analysis was performed to determine a discrimination
threshold between respiratory and cutaneous types of NSAID hy-
persensitivity with area under the curve (AUC).
Among 326 NSAID hypersensitivity patients, 45.7% (n ¼ 149)
were of the respiratory type and 54.3% (n ¼ 177) were of the cuta-
neous type, which included AECD (n ¼ 111) and AIAU (n ¼ 66). The
mean ages were 45.5 ± 13.3, 43.3 ± 11.7, and 44.0 ± 13.0 years in
AERD, AECD, and AIAU, respectively, and the proportions of male
patients were 33.6%, 39.6%, and 41.5%, respectively. In NC, the
mean age was 27.3 ± 6.3 years, and 56.3% of the subjects were
male. The mean serum periostin levels were 82.6 ± 38.8,
40.4 ± 32.5, 38.6 ± 28.9, and 46.2 ± 29.0 ng/mL in AERD, AECD,
AIAU, and NC, respectively. The serum periostin levels were signif-
icantly higher in AERD than in AECD (P < 0.001), in AIAU
(P < 0.001), and in NC (P < 0.001). However, there were no signiﬁ-
cant differences in serum periostin levels between AECD and AIAU
(P ¼ 0.708), between AECD and NC (P ¼ 0.195), and between AIAU
and NC (P ¼ 0.110) (Fig. 1). ROC curve analysis showed that the
serum periostin level could differentiate between respiratory and
cutaneous types of NSAID hypersensitivity (AUC ¼ 0.826,
P < 0.001) because the serum periostin levels were signiﬁcantly
higher in the respiratory type (82.6 ± 38.8 ng/mL) than in the cuta-
neous type (39.7 ± 31.1 ng/mL) (P < 0.001). The cut-off level was
42.5 ng/mL, with a sensitivity of 93.3% and a speciﬁcity of 61.0%
(Fig. 2).
In the present study, we found that the serum periostin levels
were signiﬁcantly higher in the respiratory type of NSAID hyper-
sensitivity than in the cutaneous type and could discriminate be-
tween these 2 phenotypes. This result has 3 clinical implications.
First, serum periostin may be used to discriminate between types
of NSAID hypersensitivity in patients who present with chest tight-
ness or dyspnea with unknown underlying disease such as asthma
and the symptoms are vague to distinguish the exacerbation of
AERD or angioedema. Second, asthma patients with high serum
periostin levels would not use NSAID because of adverse drug reac-
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Fig. 1. Comparison of serum periostin levels according to phenotypes of NSAIDs hyper-
sensitivity. Mean serum periostin level was 82.6 ± 38.8, 40.4 ± 32.5, 38.6 ± 28.9, and
46.2 ± 29.0 ng/mL in AERD, AECD, AIAU, and NC. NSAIDs, nonsteroidal anti-inﬂamma-
tory drugs; AERD, aspirin-exacerbated respiratory disease; AECD, aspirin-exacerbated
cutaneous disease; AIAU, aspirin-intolerant acute urticaria; NC, normal control.
AUC = 0.826
P < 0.001
Fig. 2. ROC curve analysis of serum periostin level in discriminating respiratory type of
NSAID hypersensitivity from cutaneous type. Cut-off level of serum periostin level was
42.5 ng/mL with 93.3% of sensitivity and 61.0% of speciﬁcity (P < 0.001). ROC, Receiver
operating characteristics; AUC, area under the curve; NSAID, nonsteroidal anti-inﬂam-
matory drugs.
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pathogenesis or prognosis between respiratory and cutaneous
types of NSAID hypersensitivity. AERD is chronic airway inﬂamma-
tion and typically shows 3 clinical characteristics-chronic rhinosi-
nusitis complicated by nasal polyp formation, moderate to severe
asthma, and hypersensitivity to aspirin/NSAIDs. These characteris-
tics may result from chronic inﬂammation with tissue damage and
remodeling, while urticaria is a totally reversible disease without
any sequelae. Unlike in urticaria, periostin is highly expressed in
skin tissue and correlates with disease severity in atopic dermatitis
which is a representative skin disease caused by allergicinﬂammation with tissue remodeling.10 Some investigations have
demonstrated that subepithelial ﬁbrosis, the most signiﬁcant
ﬁnding of airway remodeling, might be caused by periostin. IL-4
and IL-13 stimulate secretion of periostin from lung ﬁbroblasts,
and the periostin binds to extracellular matrix proteins.11 There-
after eosinophils stimulated by IL-5 migrate to areas of high perios-
tin density in an asthmatic airway through adhesion of eosinophil's
aMß2, subsequently resulting in tissue damage and ﬁbrosis.12
In conclusion, the serum periostin level can be a useful
biomarker for predicting the phenotype of AERD among NSAID hy-
persensitivity patients. It may help clinicians determine types of
NSAID hypersensitivity and predict prognosis. In addition, asthma
patients with high serum periostin levels would not use NSAID, un-
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